GEN Genetic Engineering & Biotechnology News has recognized SHIFTBIO as a leading innovator in EV-based drug delivery in the Asia-Pacific region. The article highlights how our NNP-Design AI™ platform and large-scale manufacturing capabilities are redefining the field.
Our lead program, SBI-102, harnesses macrophage reprogramming to target inflammatory diseases and is steadily progressing toward clinical entry. In parallel, we are advancing brain-targeted and inflammation-targeted delivery systems powered by our NNP-Design AI™ platform—opening new frontiers in precision medicine.
SHIFTBIO’s mission goes beyond research. We are building a future that delivers real, lasting impact for patients and society.
https://hubs.ly/Q03yKthd0
GEN Genetic Engineering & Biotechnology News has recognized SHIFTBIO as a leading innovator in EV-based drug delivery in the Asia-Pacific region. The article highlights how our NNP-Design AI™ platform and large-scale manufacturing capabilities are redefining the field.
Our lead program, SBI-102, harnesses macrophage reprogramming to target inflammatory diseases and is steadily progressing toward clinical entry. In parallel, we are advancing brain-targeted and inflammation-targeted delivery systems powered by our NNP-Design AI™ platform—opening new frontiers in precision medicine.
SHIFTBIO’s mission goes beyond research. We are building a future that delivers real, lasting impact for patients and society.
https://hubs.ly/Q03yKthd0